Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multimodality 18F-Fluciclovine PET, MRI and Cell Free Circulating DNA to Differentiate Tumor Progression From Pseudoprogression in Patients With Glioblastoma

NCT03990285 is registered in ClinicalTrials.gov with Ali Nabavizadeh as lead sponsor.

NCT NCT03990285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03990285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multimodality 18F-Fluciclovine PET, MRI and Cell Free Circulating DNA to Differentiate Tumor Progression From Pseudoprogression in Patients With Glioblastoma
Lead sponsor
Ali Nabavizadeh
Phase
Phase 1
Overall status
Completed
Start date
June 12, 2019
Completion date
November 18, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma glioblastoma multiforme